ClinicalTrials.gg
CompletedNCT04696055Updated May 13, 2025Results posted

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

A Phase 2 interventional study of Pembrolizumab and Regorafenib (Stivarga, BAY73-4506) in Hepatocellular Carcinoma, sponsored by Bayer. Completed at 39 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing pembrolizumab in Carcinoma, Hepatocellular — 10 open to participants now, 12 under way, 1 of them phase 3. pembrolizumab · Carcinoma, Hepatocellular.

Enrollment
13th of 36
95 · median 54
Started
2021
with 2 others
Phase 2
19 of 36
8 open now
Registered
25th of 36
by date
Lead sponsor
1 of 36
Bayer

Among the 36 studies testing pembrolizumab in Carcinoma, Hepatocellular, this one is the 13th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 2, and was the 25th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

10 of the 36 studies testing pembrolizumab in Carcinoma, Hepatocellular are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing pembrolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people diagnosed with liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment (advanced metastatic hepatocellular carcinoma, HCC). Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.

In this trial, the researchers will learn more about the trial treatment, regorafenib, in a small number of participants. They will study the results when the trial treatment is taken with another cancer treatment called pembrolizumab.

There will be 2 parts to this trial. The part 1 (pilot phase) will include about 52 men and women. The part 2 (expansion phase) will include about 67 men and women. All of the participants will have HCC and will be aged 18 years or older. All of the participants will have tried other treatments that did not help their HCC. These other treatments (PD-1/PD-L1 Immune Checkpoint Inhibitors) are designed to work by stopping the activity of certain proteins in the immune system thought to play a role in HCC.

During both parts of the trial, the participants will take regorafenib and receive pembrolizumab. In the pilot phase, there will be 2 groups of participants. The group that each participant joins will be based on the treatment they already received for their HCC. The researchers will review the results in each group to learn if regorafenib and pembrolizumab are helping one group of participants more than others. Outcome of this review will determine the population to be treated in the expansion phase.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Advanced or metastatic hepatocellular carcinoma (HCC)
  • Liver cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age on the day of signing .
  • Histological or cytological confirmation of HCC or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants.
  • Unresectable advanced HCC eligible for systemic therapy.
  • Participants must have progressed after only one prior line of systemic immunotherapy treatment with an /PD-L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. A wash out period of at least 28 days or 5 half-lives, whichever is shorter, must be completed for eligibility in this trial. PD-1/PD-L1 treatment progression is defined by meeting all of the following criteria:

    1. Has received at least 2 doses of an approved anti PD-1/PD-L1 mAb or received PD-1/PD-L1 treatment for 8 weeks, whichever is longer.
    2. Has demonstrated disease progression after PD-1/PD-L1 treatment as defined by 1.1. In the absence of rapid clinical progression, the initial evidence of RECIST 1.1 disease progression is to be confirmed using by a second assessment no less than four weeks from the date of the first documented progressive disease.

    i. This determination is made by the investigator. Once progressive disease is confirmed, the initial date of RECIST 1.1 progressive disease documentation will be considered that date of disease progression.

ii. In cases of unequivocal clinical or radiological progression, disease progression confirmation may not be required after documented discussion and approval by the sponsor.

c. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-1/PD-L1 mAb.

  • Participants who receive anti-PD-1 therapy as treatment following complete resection of liver cancer and have disease recurrence (unresectable locoregional disease or distant ) are eligible if they progressed while on active treatment or within 6 months of stopping anti-PD-1 therapy. This will be considered the of systemic therapy.

For these participants, the following applies:

  1. a second assessment to confirm disease progression beyond recurrence is not required; and
  2. they must have received at least 2 prior doses of anti-PD-1/PD-L1 mAb.

    • Barcelona Clinic Liver Cancer (BCLC) stage B or C.
    • Liver function status should be (CP) Class A within 7 days prior to the first dose of study intervention. CP status should be calculated based on clinical findings and laboratory results during the screening period.
    • (ECOG) Performance Status (PS) of 0 or 1 within 7 days prior to the first dose of study intervention.
    • At least one by CT scan or MRI according to RECIST 1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
    • Participants with controlled (treated) virus (HBV) infection will be allowed if they meet the following criteria:

      • Antiviral therapy for HBV must be given for at least 4 weeks and HBV viral load must be less than 500 IU/mL prior to first dose of study intervention.
      • Participants on active HBV therapy with viral loads under 500 IU/ml should stay on the same therapy throughout study treatment.
      • Participants who are anti-HBc (+), negative for HBsAg, negative for anti-HBs, and have an HBV viral load under 500 IU/mL that do not require HBV antiviral prophylaxis.
    • Provision of recent tumor tissue (as defined below) is mandatory at screening. Exceptions will be accepted for participants with no recent baseline tumor tissues after documented discussion and approval by the sponsor.

      • Tumor tissue obtained within 180 days of enrollment and after the last dose of most recent anti-cancer therapy.
      • Or a new .

Exclusion criteria

Exclusion Criteria:

  • Fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes.
  • Patients with disease that is suitable for local therapy administered with curative intent.
  • Patients who experienced any (CTCAE) ≥ 3 or any other immune- related toxicities that led to permanent discontinuation of treatment with in 1 L.
  • Persistent proteinuria of CTCAE Grade 3 or higher.
  • Diagnosis of immunodeficiency or patient is receiving chronic systemic therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study interventions.
  • Active disease.
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Any hemorrhage or bleeding event CTCAE Grade ≥ 3 within 28 days prior to the start of study medication.
  • Patients with large esophageal varices at risk of bleeding that are not being treated with conventional medical intervention.
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.
  • Ongoing infection CTCAE Grade > 2 requiring systemic therapy.
  • Dual active infection (HBsAg (+) and / or detectable HBV DNA) and infection (anti-HCV Ab (+) and detectable HCV RNA) at study entry.
  • Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg) on more than 2 separate measurements despite optimal medical management.
  • Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months).
  • Myocardial infarction less than 6 months before start of study intervention.
  • Pleural effusion or ascites that causes respiratory compromise (CTCAE Grade ≥ 2 dyspnea).
  • Patients with previous (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 3 years prior to study entry.
  • Known active central nervous system (CNS) and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable.
  • Significant acute gastrointestinal disorders with diarrhea as a major symptom.
  • Prior monotherapy treatment with any tyrosine kinase inhibitor in 1L.
  • Prior treatment with regorafenib, in combination regimens with immune checkpoint inhibitors.
  • Transfusion of blood products within 7 days prior to signing , or administration of colony stimulating factors within 4 weeks prior to signing informed consent.
  • Previous assignment to treatment during this study.
  • Previous (at least a minimum of 28 days, or 5 half-lives of an drug before the start of study treatment, whichever is shorter) or concomitant participation in another clinical study with investigational medicinal product(s).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Regorafenib+Pembrolizumab

    Participants with advanced hepatocellular carcinoma (HCC) progressed on 1L anti-PD-1/PD-L1 therapy.

    Drug: Pembrolizumab · Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

  • Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).

    Also known as: Keytruda / MK-3475

  • Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment

    Overall response rate (ORR) is defined as the percentage of participants with best overall response of confirmed complete response (CR) or partial response (PR). ORR per RECIST 1.1 by independent central assessment is reported). RECIST 1.1: response evaluation criteria in solid tumors version 1.1

    Time frame: Up to 15 months. Data up to 38 months are now available and are also reported for full transparency.

Secondary outcomes

  1. Overall Response Rate (ORR) Per RECIST 1.1 by Investigator Assessment

    Overall response rate (ORR) is defined as the percentage of participants with best overall response of confirmed complete response (CR) or partial response (PR). ORR by RECIST 1.1 investigator review is reported. RECIST 1.1: response evaluation criteria in solid tumors version 1.1

    Time frame: Up to 38 months

  2. Duration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment

    Duration of response (DOR) for partial response (PR) and complete response (CR) was defined as the time from the first documented objective response of PR or CR, whichever noted earlier, to disease progression or death (if death occurs before progression was documented). DOR was defined for confirmed responders only, i.e., participants with a CR or PR. RECIST 1.1: response evaluation criteria in solid tumors version 1.1

    Time frame: Up to 38 months

  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was considered as treatment-emergent (TEAE) if arising or worsening after start of first study intervention administration until 30 days after administration of any study intervention. In addition, any AEs qualifying as a serious adverse event (SAE) were collected for 90 days after the last dose of pembrolizumab, unless a new anti-cancer therapy had been initiated.

    Time frame: Up to 38 months

  4. Number of Participants With Safety-relevant Changes in Clinical Parameters

    Number of participants with clinically relevant trends observed in laboratory data, ECG data, or ECOG performance status is reported.

    Time frame: Up to 38 months

  5. Percentage of Participants With Dose Modification

    Dose modification included dose interruption, dose reduction, dose discontinuation.

    Time frame: Up to 38 months

07

Results

Posted May 30, 2023

Participant flow

The study was conducted between 03 February 2021 (first participant first visit) and 23 April 2024 (last participant last visit) at 39 centers in 8 countries.

Participant flow — Overall Study
MilestoneCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Started6827
Completed00
Not completed6827
Withdrew: Adverse event102
Withdrew: Death40
Withdrew: Other72
Withdrew: Physician decision30
Withdrew: Progressive disease - clinical progression11
Withdrew: Progressive disease - radiological progression4220
Withdrew: Subject decision12

Outcome measures

PrimaryOverall Response Rate (ORR) Per RECIST 1.1 by Central Assessment

Overall response rate (ORR) is defined as the percentage of participants with best overall response of confirmed complete response (CR) or partial response (PR). ORR per RECIST 1.1 by independent central assessment is reported). RECIST 1.1: response evaluation criteria in solid tumors version 1.1

Time frame:
Up to 15 months. Data up to 38 months are now available and are also reported for full transparency.
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment
Percentage of participantsCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Up to 15 months (primary outcome as previously reported)5.9 (1.6 to 14.4)11.1 (2.4 to 29.2)
Up to 38 months (as of study completion)7.4 (2.4 to 16.3)14.8 (4.2 to 33.7)
SecondaryOverall Response Rate (ORR) Per RECIST 1.1 by Investigator Assessment

Overall response rate (ORR) is defined as the percentage of participants with best overall response of confirmed complete response (CR) or partial response (PR). ORR by RECIST 1.1 investigator review is reported. RECIST 1.1: response evaluation criteria in solid tumors version 1.1

Time frame:
Up to 38 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per RECIST 1.1 by Investigator Assessment
Percentage of participantsCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Overall Response Rate (ORR) Per RECIST 1.1 by Investigator Assessment7.4 (2.4 to 16.3)18.5 (6.3 to 38.1)
SecondaryDuration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment

Duration of response (DOR) for partial response (PR) and complete response (CR) was defined as the time from the first documented objective response of PR or CR, whichever noted earlier, to disease progression or death (if death occurs before progression was documented). DOR was defined for confirmed responders only, i.e., participants with a CR or PR. RECIST 1.1: response evaluation criteria in solid tumors version 1.1

Time frame:
Up to 38 months
Reported as:
Median · Days
Duration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment
DaysCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Central assessment210 (158 to 937)195 (83 to 280)
Investigator assessment431 (82 to 893)364 (117 to 839)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was considered as treatment-emergent (TEAE) if arising or worsening after start of first study intervention administration until 30 days after administration of any study intervention. In addition, any AEs qualifying as a serious adverse event (SAE) were collected for 90 days after the last dose of pembrolizumab, unless a new anti-cancer therapy had been initiated.

Time frame:
Up to 38 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Any TEAE6827
Any SAE3711
SecondaryNumber of Participants With Safety-relevant Changes in Clinical Parameters

Number of participants with clinically relevant trends observed in laboratory data, ECG data, or ECOG performance status is reported.

Time frame:
Up to 38 months
Reported as:
Count of participants · Participants
Number of Participants With Safety-relevant Changes in Clinical Parameters
ParticipantsCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Number of Participants With Safety-relevant Changes in Clinical Parameters00
SecondaryPercentage of Participants With Dose Modification

Dose modification included dose interruption, dose reduction, dose discontinuation.

Time frame:
Up to 38 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Dose Modification
Percentage of participantsCohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])
Regorafenib - drug interruptions or delays63.270.4
Regorafenib - dose reductions41.263.0
Regorafenib - drug withdrawal16.225.9
Pembrolizumab - dose interruptions or delays14.725.9
Pembrolizumab - drug withdrawal4.411.1

Adverse events

Collected over These data extend to the final release date of the clinical database (38 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib+Pembrolizumab [1L: Atezolizumab + Bevacizumab]53/68 (77.9%)37/68 (54.4%)63/68 (92.6%)
Regorafenib+Pembrolizumab [Any Other IO Containing Treatment]20/27 (74.1%)11/27 (40.7%)27/27 (100%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventRegorafenib+Pembrolizumab [1L: Atezolizumab + Bevacizumab]Regorafenib+Pembrolizumab [Any Other IO Containing Treatment]
Blood bilirubin increasedInvestigations2/682/27
SepsisInfections and infestations3/681/27
Acute myocardial infarctionCardiac disorders0/681/27
ColitisGastrointestinal disorders0/681/27
Lower gastrointestinal haemorrhageGastrointestinal disorders0/681/27
PyrexiaGeneral disorders0/681/27
General physical health deteriorationGeneral disorders1/681/27
CholangitisHepatobiliary disorders0/681/27
PneumoniaInfections and infestations1/681/27
Urinary tract infection pseudomonalInfections and infestations0/681/27
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRegorafenib+Pembrolizumab [1L: Atezolizumab + Bevacizumab]Regorafenib+Pembrolizumab [Any Other IO Containing Treatment]
AstheniaGeneral disorders23/6818/27
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders27/6814/27
DiarrhoeaGastrointestinal disorders23/6813/27
Decreased appetiteMetabolism and nutrition disorders21/6813/27
ArthralgiaMusculoskeletal and connective tissue disorders13/6810/27
HypertensionVascular disorders15/689/27
COVID-19Infections and infestations3/686/27
Blood bilirubin increasedInvestigations9/686/27
RashSkin and subcutaneous tissue disorders10/686/27
Abdominal painGastrointestinal disorders15/685/27

Baseline characteristics

Full Analysis Set (FAS): all participants who took at least 1 dose of study intervention

Age, Continuous
Age, Continuous(Years)Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])Total
Mean61.7 ± 13.170.9 ± 7.364.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])Total
Female15722
Male532073
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])Total
Hispanic or Latino7310
Not Hispanic or Latino501767
Unknown or Not Reported11718
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab])Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment])Total
American Indian or Alaska Native000
Asian19322
Native Hawaiian or Other Pacific Islander000
Black or African American202
White372057
More than one race101
Unknown or Not Reported9413
08

Study locations

39 sites
  • University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • City of Hope - Duarte Cancer Center
    Duarte, California 91010, United States
  • USC Norris Hospital and Clinics
    Los Angeles, California 90033, United States
  • University of California Irvine Medical Center
    Orange, California 92868-3201, United States
  • Medical Oncology Hematology Consultants, PA
    Newark, Delaware 19713, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2696, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1023, United States
  • Hôpital Beaujon - Clichy
    Clichy, 92110, France
  • Center Hospitalier Michallon - Grenoble
    Grenoble Cedex 9, 38043, France
  • Hopital Claude Huriez - Lille
    Lille, 59037, France
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
  • AP-HM - Hopital de la Timone
    Marseille, 13005, France
  • Hôpital Saint-Eloi
    Montpellier Cedex, 34059, France
  • Centre François Magendie - Pessac
    Pessac, 33600, France
  • Centre Hospitalier Universitaire de Nancy
    Vandoeuvre-les-nancy, 54500, France
  • Hôpital Paul Brousse - Villejuif
    Villejuif, 94800, France
  • Eberhard-Karls-Universität Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • Klinikum der Universität München Grosshadern
    München, Bayern 81377, Germany
  • Heinrich-Heine-Universität Düsseldorf
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Universitätsklinikum Köln
    Köln, Nordrhein-Westfalen 50937, Germany
  • Universitätsmedizin der Johannes Gutenberg Universität Mainz
    Mainz, Rheinland-Pfalz 55101, Germany
  • Rambam Health Corporation
    Haifa, 3109601, Israel
  • Rabin Medical Center | Beilinson Hospital - Internal Medicine C Department
    Petach Tikva, 4941492, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Humanitas Mirasole S.p.A.
    Milano, Lombardia 20089, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Lombardia 20122, Italy
  • Azienda Ospedaliero Universitaria Pisana_Santa Chiara - UO Oncologia 2
    Pisa, Toscana 56126, Italy
  • Istituto Oncologico Veneto_Padova - UOC Oncologia 1
    Padova, Veneto 35128, Italy
  • Chiba University Hospital
    Chiba-shi, Chiba 260-8677, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Japanese Red Cross Society Musashino Red Cross Hospital
    Musashino, Tokyo 180-8610, Japan
  • Asan Medical Center
    Seoul, Seoul Teugbyeolsi 05505, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 3080, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Institut Català d'Oncologia Hospitalet
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, 8036, Spain
  • Hospital General Universitario Gregorio Marañón | Digestivo
    Madrid, 28007, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2022, 15 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 15 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2021
First posted
Jan 6, 2021
StartActual
Feb 3, 2021
Primary completionActual
May 5, 2022
CompletionActual
Apr 23, 2024
Results first posted
May 30, 2023
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04696055
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 6, 2021
Start date
Feb 3, 2021
Primary completion
May 5, 2022
Completion
Apr 23, 2024
Results posted
May 30, 2023
Last update
May 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Regorafenib

Start the discussion